CASP8 and prostate carcinoma: CASP8, as a member of the cysteoaspartic enzyme family, has dual roles in cell death and survival; its nonapoptotic function confers resistance to enzalutamide in prostate cancer; and its high expression is often associated with poor prognosis of prostate cancer [34], which is consistent with our SMR results.